Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | HTR1A | P08908 | 2/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.77 |
| ▸ | HTR2C | P28335 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.73 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.70 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.70 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
| ▸ | STAT3 | P40763 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743907 | 1.00 | ALDH1A1 (0.77) | ALDH1A1KDM4EHPGDHTR1AGAA | |
| SCHEMBL30179914 | 0.93 | CYP1A2 (0.87) | ALDH1A1KDM4EHPGDHTR1AGAA | |
| SCHEMBL10468494 | 0.92 | KDM4E (0.81) | ALDH1A1KDM4EHPGDHTR1AGAA | |
| SCHEMBL10468496 | 0.92 | KDM4E (0.81) | ALDH1A1KDM4EHPGDHTR1AGAA | |
| SCHEMBL2744131 | 0.90 | NFKB1 (0.68) | ALDH1A1KDM4EHPGDHTR1AGAA | |
| SCHEMBL2744128 | 0.90 | NFKB1 (0.68) | ALDH1A1KDM4EHPGDHTR1AGAA | |
| SCHEMBL2743902 | 0.89 | TUBB4A (0.73) | ALDH1A1KDM4EHPGDHTR1AGAA | |
| SCHEMBL2743899 | 0.89 | TUBB4A (0.73) | ALDH1A1KDM4EHPGDHTR1AGAA | |
| SCHEMBL6106506 | 0.87 | ALDH1A1 (0.74) | ALDH1A1KDM4EHPGDHTR1AGAA | |
| Sinapic Acid Methyl Ether SCHEMBL207442 | 0.87 | KDM4E (1.00) | ALDH1A1KDM4EHPGDHTR1AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | claimed |
| US-8178727-B2 | Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer | NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20030008914-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-09 | — | — | US | disclosed |
| US-20020177723-A1 | Compounds and methods for the treatment of inflammatory and immune disorders | LEUKOSITE, INC. | 2002-11-28 | — | — | US | disclosed |
| US-6420392-B1 | PAF RECEPTOR ANTAGONISTS AND/OR BY INHIBITING THE ENZYME 5-LIPOXYGENASE. | MILLENNIUM PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| US-6294574-B1 | THERAPY OF DISORDER CAUSED BY PLATELET ACTIVATION FACTOR BY TRANS-2-(5-N'-METHYL-N'-HYDROXYUREIDYLMETHYL)-3-METHOXY-4-P-CH LOROPHENYLTHIOETHOXPHENYL)-5-(3,4,5-TRIMETHOXPHENYL)TETRAHYDRO FURAN OR ITS SALT | CYTOMED, INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1123095-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | Millennium Pharmaceuticals, Inc. (US) | 2001-08-16 | — | — | EP | disclosed |
| EP-0650485-B1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED INC (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000023071-A9 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | LEUKOSITE INC (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-1995018610-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| EP-0650485-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1995-05-03 | — | — | EP | disclosed |
| US-5358938-A | 2,5-Diaryl tetrahydrofurans, tetrahydrothiophenes, 1,3-cyclo-pentanes and pyrrolidines | CYTOMED, INC. (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994001430-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| US-5114961-A | 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists | MERCK & CO., INC. (US) | 1992-05-19 | — | — | US | disclosed |
| US-5010100-A | Skeletal muscular disorders, hydertensive agents, cardiovascular disorders | MERCK & CO. INC. (US) | 1991-04-23 | — | — | US | disclosed |
| US-4996203-A | Platelet-activating factor antagonists | MERCK & CO., INC. (US) | 1991-02-26 | — | — | US | disclosed |
| EP-0402150-A1 | New 2,5-diaryl tetrahydrofurans and analogs therof as PAF antagonists | MERCK & CO. INC. (US) | 1990-12-12 | — | — | EP | disclosed |
| EP-0402151-A1 | New 2, 5-diaryl tetrahydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1990-12-12 | — | — | EP | disclosed |
| US-4977146-A | ANTICOAGULANT | MERCK & CO., INC. (US) | 1990-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | MYC, CCNE2, CCNE1 | ALDH1A1 614/4885KDM4E 623/4885HPGD 1340/4885 |
| US-20030008914-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | ALOX5, ALOX5AP, ALOX15 | ALDH1A1 175/4885KDM4E 525/4885HPGD 95/4885 |
| US-20020177723-A1 | Compounds and methods for the treatment of inflammatory and immune disorders | LTB4R2, LTC4S, LTB4R | ALDH1A1 556/4885KDM4E 3525/4885HPGD 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.